647 POSTER A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

✍ Scribed by R. Cohen; D. Camidge; S. Diab; L. Gore; L. Chow; C. O'Bryant; E. Temmer; F. Fox; H. Youssoufian; S. Eckhardt

• Book ID: 118624275
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 59 KB
• Volume: 4
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(06)70652-8